Epstein-Barr virus (EBV) is one of the most ubiquitous infectious viruses with 490% of the world's population infected with this human herpes virus. 1, 2 In the immunocompetent host, EBV latently infects B cells without any pathological disorders, but a significant role of EBV has also been suggested in the pathogenesis of a number of diseases of (non-)hematological origin. [3] [4] [5] [6] In immuneincompetent patients, such as patients after stem cell and solid organ transplantation, post transplant lymphoproliferative disease (PTLD: median onset 3 months, range 1 week to 9 years) is a well-known complication associated with EBV reactivation. The incidence ranges from 1 to 20% in haematopoietic stem cell transplantation (SCT) recipients, with markedly increased incidences in patients receiving T-cell depleted grafts. 3, 4 Haemophagocytic lympho-histiocytosis (HLH) is a very rare complication after SCT. 6, 7 Here, we report a unique case of a patient who developed a HLH syndrome with high EBV loads detected in the NK-cell compartment of the peripheral blood.
A 2-year-old girl was diagnosed in May 2003 with Hurler Syndrome, and was on enzyme replacement therapy (laronidase) weekly since July 2003. She received an unrelated cord blood transplant (human leukocyte antigen match: five out of six according to Rubinstein criteria: 10 Â 10 7 nucleated cells/kg) on 31 December 2003, after a conditioning regimen based on oral busulfan (16 mg/kg), IV antithymocyte globulin (ATG: 10 mg/kg) and IV cyclophosphamide (200 mg/kg). Unfortunately, there was an early graft rejection. In August 2004, she received a maternal haplo-identical SCT (a combination of bonemarrow and peripheral blood stem cells (PBSCs)). PBSCs were CD34 þ selected cells (CliniMACS, Miltenyi Biotec, Bergisch Gladbach, Germany). The bone marrow was depleted using CD2/3 and CD19/20 antibodies. That combination of bone marrow and PBSCs was given based on the possible favourable effect on engraftment of stromal cells present in bone marrow. She received a total of 27 Â 10 6 CD34 þ /kg, 3.7 Â 10 4 CD3 þ /kg and 1.6 Â 10 5 CD20 þ /kg. The conditioning regimen consisted of fludarabine IV (total 180 mg/kg), thiotepa IV (total 10 mg/m 2 ), melphalan IV (total 140 mg/m 2 ) and ATGfresenius IV (40 mg/kg). She developed an 'engraftment syndrome' during the second week, and was out of aplasia on the day þ 12. She was discharged 4 weeks after SCT. On whole blood complete (100%) donor chimerism was found. One week after discharge, she was readmitted with fever, lymphadenopathy, hepato-splenomegaly and a plasmatic EBV load of 18 000 copies/ml (see Figure 1) . Lymphocyte phenotyping showed 150 CD20 þ /ml, 600 CD56/ CD16 þ /ml, 100 CD4 þ /ml and 650 CD8 þ /ml. Suspecting the diagnosis of PTLD, we decided to start anti-CD20-globulin (375 mg/m 2 /week: three times). Three days after the first dose of anti-CD20 she clinically deteriorated associated with a significant increase of the plasmatic EBV load (4200 000 copies/ml) and haemophagocytosis (documented by bone marrow aspirate and fulfilling the diagnostic criteria according to the HLH Study Group of the Histiocyte Society:
8 pancytopenia, splenomegaly, ferritine of 3244 mg/l, hypofibrinogenemia of 1.4 g/l and hypertriglyceridemia of 5.3 mmol/l). 3 Dexamethasone was started (10 mg/m 2 /day), and was tapered when the patient came in clinical remission (10 days after admission). A significant decrease of the viral load as well as an improvement of the general condition was observed: the fever disappeared, the fibrinogen level increased and the triglycerides level decreased as well as the ferritine level. We found neither other infections nor other viral reactivations during the course of disease (blood cultures negative, plasmatic polymerase chain reactions (PCRs) for cytomegalovirus, HHV6 and adenovirus negative). Twentyfour months after SCT the patient remains disease free with normal enzyme activity (alpha-L-iduronidase) and 100% donor chimerism. Plasmatic viral loads, as well as viral load in the various cell fractions, remain negative until now.
The increase of plasmatic EBV load after anti-CD20 therapy might be due to massive outflow of EBV from the lysed B cells. However, because of the clinical deterioration we suspected other cell fractions to be EBV positive. Using the CliniMACS R cell selection system, CD19 þ , CD3 þ and CD16/56 þ (NK) cells (95% purified) were positively selected. We measured viral loads on those cell fractions (copies/10 5 cells) by EBV-DNA PCR. A very high intracellular viral load in the NK cells, and a lower viral load in the T cells was found (see Figure 1) . As we suspected transmission of EBV owing to infected NK cells of the donor, plasmatic and intracellular load in T-, NK-and B cells of the donor was measured. The viral loads in the various cell fractions of the haplo-donor were 16 000 copies/10 5 NK cells, 200 copies/10 5 T cells, 500 copies/10 5 B cells and plasmatic loads were negative. The most frequent EBV-associated complication post-SCT is PTLD, sometimes even of NK-cell origin.
3,4,9 HLH post-SCT has been described only a few times, mainly after autologous SCT. 5, 7, 10 An association with EBV, however, has never been described. However, ectopic-EBV infection in T cells or NK cells has been reported in EBV-associated haematological/immunological diseases, such as acute fulminant EBV-associated HLH and chronic active EBV infection. 5, 6 Kasahara and Yachie 5 reviewed these cell type-specific infections of EBV, and showed that in EBV-HLH various cell types could be infected, for example, CD4 þ , CD8 þ , CD16 þ and CD56 þ . In our patient, the HLH was associated with abundant presence of EBV-DNA in NK (CD16/56 þ ) cells and could probably occur owing to latent-infected NK cells of donor origin. The more than 1 log increase in plasmatic viral load after anti-CD20 therapy and the high intra-NK-cell viral load in donor and recipient support this theory. NK cells were present in the graft owing to the addition of T-and B-cell depleted bone marrow (leaving NK cells in this part of the graft used) to the CD34 þ selected PBSC. How EBV can cause a latent infection of the NK cells in the mother is an interesting and highly speculative question. The receptor for EBV on NK cells is not known; some propose that EBV can enter into the NK cell through CD-21-like proteins. Studies to explore the cause of latent NK infection would be of great interest. Here, we described a unique case of EBV-HLH after haplo-identical SCT owing to EBV-infected NK cell from the donor. Fortunately, our patient reacted very well to systemic steroids and anti-CD20 þ antibodies. In patients without sufficient reaction to anti-CD20 þ treatment, EBV PCRs on sorted cells should be considered. 
